PlainPharmaWatch

CMS Open Payments · Program Year 2024

Life Molecular Imaging Ltd

Life Molecular Imaging Ltd reported $251,721.63 across General Payments, Research, and Ownership to 353 physicians and teaching hospitals across 354 transactions.

$251.7K
All-tracks total
354
Transactions
353
Recipients
+$3.0K
General Payments vs PY2023

Life Molecular Imaging Ltd reported $251,721.63 across all CMS Open Payments tracks (General + Research + Ownership) to 353 physicians and teaching hospitals in Program Year 2024 - ranking #937 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $8,046.63, averaging $713.09 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer life-molecular-imaging-ltd Life Molecular Imaging Ltd

$251.7K · #937/1,925 · 0.0% industry · PY2024

  • TOT $251.7K
  • RANK #937
  • SHARE 0.0%
  • TXN 354
  • RCP 353
  • CAT 1
  • GEN $8.0K
  • ΔGEN +$3.0K
  • TOP1 2.9%
  • PY 2024

Nearest volume peer: Clinigen, Inc. ($251.9K)

Essential Medical, Inc.$252.4KClinigen, Inc.$251.9KLife Molecular Imaging Ltd (…$251.7KElucent Medical$251.3KElectromed, Inc.$249.6K
All-tracks payment totals near Life Molecular Imaging Ltd (CMS Open Payments PY2024)

Life Molecular Imaging Ltd sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Life Molecular Imaging Ltd's CMS-reported General Payments increased by $3.0K (+60.7%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: LIFE MOLECULAR IMAGING LTDPY2023: LIFE MOLECULAR IMAGING LTDPY2024: Life Molecular Imaging Ltd. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$5.0KPY2024$8.0K
PY2023
$5,006.06
PY2024
$8,046.63

What the Data Shows for Life Molecular Imaging Ltd

Life Molecular Imaging Ltd ranks #937 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $251,721.63 across 354 transactions to 353 physicians and teaching hospitals - $711.08 per transaction and $713.09 per recipient on average.

353 transactions worth $8.0K make "Food and Beverage" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Food and Beverage" leads Life Molecular Imaging Ltd's 1-category general-payment breakdown at $8.0K, 100.0% of the reported total.

How Life Molecular Imaging Ltd divides its payments

General-payment categories, ordered by reported total

1. Food and Beverage$8.0K
Payment Type Amount Transactions
Food and Beverage $8.0K 353

Recipient Concentration in General Payments

The five largest recipient relationships account for $861.25 (10.7%) of $8,046.63 in this company's General Payments records across 286 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Life Molecular Imaging Ltd

The five named recipients with the highest reported General Payments from this company

Cara Leahy$230.79Kevin Berger$209.73Raymond Turner$150.73Todd Rexford$135.00Kevin Foley$135.00
  1. 1

    Cara Leahy

    $230.79 across 2 reported transactions

  2. 2

    Kevin Berger

    $209.73 across 3 reported transactions

  3. 3

    Raymond Turner

    $150.73 across 1 reported transactions

  4. 4

    Todd Rexford

    $135.00 across 1 reported transactions

  5. 5

    Kevin Foley

    $135.00 across 1 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Life Molecular Imaging Ltd's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Life Molecular Imaging Ltd.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Life Molecular Imaging Ltd.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Life Molecular Imaging Ltd's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.